Status: Recruiting
Linperlisib Combined With Chidamide in Patients With PTCL
The phase Ib part of this study aims to determine the recommended phase II dose （RP2D）of linperlisib in combination with chidamide for the treatment of peripheral T-cell lymphoma (PTCL). The phase IIa part is designed to evaluate the preliminary efficacy and safety of the linperlisib plus chidamide regimen in newly diagnosed PTCL patients. The phase IIb part compares the efficacy and safety of linperlisib combined with chidamide versus the standard CHOP (CHOP-like) regimen in newly diagnosed PTCL patients.
Participants needed: 134
Trial details
Phase: Phase 1, Phase 2Age: 18-80Biological sex: AllType: InterventionalSponsor: Yanyan LiuUpdated: Dec 5, 2025Locations: 6
Eligibility criteria
Age 18-75 years at the time of inclusion (Age 18-80 years for phase Ib and IIa s... [+7]
Patients previously treated with PI3K inhibitor [+10]